Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xingnaojing for Acute Ischemic Stroke (PUBLISH)
NCT05559307Phase 4Unknown
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- HM (Herbal Medicine), Combination Drug
- Countries
- 1
01
Overview
Phase 4, open-label trial of Xingnaojing injection in ischemic stroke (2 arms). Primary endpoint: Differences in Borneol, Muscone, 1,8-Cineole concentrations in plasma and urine at 8 days. Status: unknown.
02
Drugs
Xingnaojing injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05559307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559307.